Skip to main content Accessibility help
×
Home
Hostname: page-component-6c8bd87754-ncgjf Total loading time: 0.418 Render date: 2022-01-19T19:18:55.456Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Book contents

34 - Management of the lymphomas and myeloma

Published online by Cambridge University Press:  05 November 2015

Eve Gallop-Evans
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Louise Hanna
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access

Summary

Introduction

The incidence of lymphoma is rising, and current attention is focused not just on improving cure rates, but also on minimising late effects of treatment. Patients should be managed by multidisciplinary teams that bring together the appropriate expertise of haematologists, oncologists, radiologists, pathologists and specialist nurses. Management guidelines are produced by the British Committee for Standards in Haematology (BCSH) and are a useful resource.

Lymphomas

Introduction

The World Health Organisation (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues was first published in 2001 and updated in 2008 (Table 34.1: Swerdlow et al., 2008). This distinguishes more than 60 specific entities on the basis of morphologic, immunophenotypic, genetic, molecular and clinical features, stratified according to cell lineage and derivation from precursor or mature lymphoid cells.

Non-Hodgkin lymphoma (NHL) is the sixth most common cancer in the UK, with over 12,000 patients diagnosed each year, accounting for 4% of all new cases of cancer. The incidence is related to age, with the majority of cases diagnosed over the age of 65 years. Nearly half of all cases diagnosed in the UK are diffuse large B cell lymphoma (DLBCL, 48%). Marginal zone lymphomas (MZL) and follicular lymphoma (FL) account for 20% and 19%, respectively, with T cell lymphomas (6%), mantle cell lymphoma (MCL, 5%) and Burkitt lymphoma (2%) making up the remainder. Crude incidence rates in the UK range from 0.2 to 9 cases per 100,000.

Hodgkin lymphoma (HL) accounts for 0.6% of all cancer cases, with a relatively stable incidence of around 1700 cases per year. In children under 14 years of age, lymphoma is the third most common cancer after leukaemia and brain tumours. Lymphomas are the most common cancer in teenagers and young adults, accounting for 21% of cancers in this age group, with two-thirds of these being HL.

Aetiology

The aetiology of lymphoma is not clearly understood and appears to be multifactorial. The most significant risk factor is immune dysfunction which may be secondary to viral infection (e.g. HIV, HBV, HCV, EBV, HTLV-1), autoimmune disease or iatrogenic immunosuppression (Roman and Smith, 2011). Mucosa-associated lymphoid tissue (MALT) lymphomas are associated with antigenic stimulation by infectious agents including Helicobacter pylori, Chlamydia psittaci and Borrelia burgdorferi.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ardeshna, K. M., Smith, P., Qian, W., et al. (2010). An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with Stage II, III, IV, asymptomatic, non-bulky gollicular lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis. ASH Annual Meeting Abstracts, available at https://ash.confex.com/ash/2010/webprogram/Paper27692.html (accessed December 2014).
Benton, E. C., Crichton, S., Talpur, R., et al. (2013). A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur. J.Cancer, 49, 2859–2868.CrossRefGoogle ScholarPubMed
Bird, J. M., Owen, R. G., D'Sa, S.,et al. (2011). Guidelines for the diagnosis and management of multiple myeloma 2011. Br. J. Haematol., 154, 32–75.CrossRefGoogle ScholarPubMed
Chen, R. C., Chin, M. S.Ng, A. K., et al. (2010). Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J. Clin. Oncol., 28, 136–141.Google ScholarPubMed
Cheson, B. D., Fisher, R. I., Barrington, S. F., et al. (2014). Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano Classification. J. Clin. Oncol. 32, 3059–3068.CrossRef
Cunningham, D., Hawkes, E. A., Jack, A., et al. (2013). Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet, 381, 1817–1826.CrossRefGoogle ScholarPubMed
Dearden, C. E., Johnson, R., Pettengell, R., et al. (2011). Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br. J. Haematol., 153, 451–485.CrossRefGoogle Scholar
Dunleavy, K., Pittaluga, S., Maedal, S., et al. (2013). Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N. Engl. J. Med., 368, 1408–16.CrossRef
Eich, H. T., Diehl, V., Görgen, H., et al. (2010). Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 Trial. J. Clin. Oncol., 28, 4199–4206.CrossRefGoogle Scholar
Eichenauer, D., Plutschow, A., Fuchs, M., et al. (2015). Long-term course of patients with Stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group J. Clin. Oncol., DOI: 10.1200/JCO.2014.60.4363.CrossRef
El-Galaly, T. C., D'Amore, F., Mylam, K. J., et al. (2012). Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J. Clin. Oncol., 30, 4508–4514.CrossRefGoogle ScholarPubMed
Engert, A., Plütschow, A., Eich, H. T., et al. (2010). Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N. Engl. J. Med., 363, 640–652.CrossRefGoogle ScholarPubMed
Federico, M., Bellei, M., Marcheselli, L., et al. (2009). Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J. Clin. Oncol., 27, 4555–4562.CrossRefGoogle ScholarPubMed
Ferreri, A. J., Cwynarski, K., Pulczynski, E., et al. (2015). Addition of thiotepa and rituximab to antimetabolites significantly improves outcomes in primary CNS lymphoma: first randomization of the IELSG32 trial. Haematol. Oncol., 33, Supplement S1:1-20, abstract 009.
Ferreri, A. J., Reni, M., Foppoli, M., et al. (2009). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet, 374, 1512–1520.CrossRefGoogle ScholarPubMed
Feugier, P., Van Hoof, A., Sebban, C., et al. (2005). Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-Cell lymphoma: a study by the Groupe D'Etude des Lymphomes de l'Adulte. J. Clin. Oncol., 23, 4117–4126.CrossRefGoogle ScholarPubMed
Gallamini, A., Hutchings, M., Rigacci, L., et al. (2007). Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol., 25, 3746–3752.CrossRefGoogle ScholarPubMed
Girinsky, T., van der Maazen, R. and Specht, L. (2006). Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother. Oncol., 79, 270–277.CrossRefGoogle ScholarPubMed
Girinsky, T., Specht, L., Ghalibafian, M., et al. (2008). The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother. Oncol., 88, 202–210.CrossRefGoogle ScholarPubMed
Gisselbrecht, C., Glass, B., Mounier, N., et al. (2010). Salvage regimens with autologous transplantation for relapsed large B-Cell lymphoma in the rituximab era. J. Clin. Oncol., 28, 4184–4190.CrossRefGoogle ScholarPubMed
Goda, J. S., Gospodarowicz, M., Pintilie, M., et al. (2010). Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer, 116, 3815–3824.CrossRefGoogle ScholarPubMed
Greipp, P. R., Miguel, J. S., Durie, B. G. M., et al. (2005). International staging system for multiple myeloma. J. Clin. Oncol., 23, 3412–3420.CrossRefGoogle ScholarPubMed
Guadagnolo, B., Li, S., Neuberg, D., et al. (2006). Long-term outcome and mortality trends in early-stage, Grade 1–2 follicular lymphoma treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 64, 928–934.CrossRefGoogle ScholarPubMed
Hasenclever, D., Diehl, V., Armitage, J. O., et al. (1998). A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N. Engl. J. Med., 339, 1506–1514.CrossRefGoogle ScholarPubMed
Held, G., Murawski, N., Ziepert, M., et al. (2014). Role of radiotherapy to bulky disease in elderly patients with aggressive B-Cell lymphoma. J. Clin. Oncol., 32, 1112–1118.CrossRefGoogle ScholarPubMed
Hodgson, D. C., Dieckmann, K., Terezakis, S., et al. (2014). Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Pract. Radiat. Oncol., 5, 85–92.CrossRef
Horning, S. J., Weller, E., Kim, K., et al. (2004). Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. J. Clin. Oncol., 22, 3032–3038.CrossRefGoogle ScholarPubMed
Hoskin, P., Kirkwood, A., Popova, B., et al. (2013a). FoRT: a phase 3 multi-center prospective randomized trial of low dose radiation therapy for follicular and marginal zone lymphoma. Int. J. Radiat. Oncol. Biol. Phys., 85, 22.CrossRefGoogle Scholar
Hoskin, P. J., Diez, P., Williams, M., et al. (2013b). Recommendations for the use of radiotherapy in nodal lymphoma. Clin. Oncol. (R. Coll. Radiol.), 25, 49–58.CrossRefGoogle ScholarPubMed
Hutchings, M., Loft, A., Hansen, M., et al. (2006). FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107, 52–59.CrossRefGoogle ScholarPubMed
Illidge, T., Specht, L., Yahalom, J., et al. (2014). Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int. J. Radiat. Oncol. Biol.Phys., 89, 49–58.CrossRef
Jiang, M., Zhang, H., Jiang, Y., et al. (2012). Phase 2 trial of ‘sandwich’ L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer, 118, 3294–3301.CrossRefGoogle Scholar
Khan, A. B., Barrington, S. F., Mikhaeel, N. G., et al. (2013). PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood, 122, 61–67.CrossRefGoogle ScholarPubMed
Knobel, D., Zouhair, A., Tsang, R. W., et al. (2006). Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. B. M. C. Cancer, 6, 118.CrossRefGoogle ScholarPubMed
Lister, T. A., Crowther, D., Sutcliffe, S. B., et al. (1989). Report of a commettee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswold meeting. J. Clin. Oncol., 7, 1630–1636.CrossRefGoogle Scholar
Lowry, L., Smith, P., Qian, W., et al. (2011). Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother. Oncol., 100, doi: 10.1016/j.radonc.2011.05.013. Epub 2011 Jun 12.CrossRefGoogle ScholarPubMed
Majhail, N. S., Rizzo, J. D., Lee, S. J., et al. (2012). Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transpl., 47, 337–341.CrossRefGoogle ScholarPubMed
Marcus, R., Imrie, K. and Solal-Celigny, P. (2008). Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol., 26, 4579–4586.CrossRefGoogle ScholarPubMed
McKay, P., Leach, M., Jackson, R., et al. (2012). Guidelines for the investigation and management of mantle cell lymphoma. Br. J. Haematol., 159, 405–426.CrossRefGoogle ScholarPubMed
McMillan, A., Ardeshna, K. M., Cwynarski, K., et al. (2013). Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. Br. J. Haematol., 163, 168–181.Google ScholarPubMed
McNamara, C., Davies, J., Dyer, M., et al. (2011). Guidelines on the investigation and management of follicular lymphoma. Br. J. Haematol., 156, 446–467.Google ScholarPubMed
Meignan, M., Barrington, S., Itti, E., et al. (2014). Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012. Leuk. Lymphoma, 55, 31–37.CrossRefGoogle ScholarPubMed
Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., et al. (2005). Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J. Clin. Oncol., 23, 4634–4642.CrossRefGoogle Scholar
Miller, T. P., Dahlberg, S., Cassady, J. R., et al. (1998). Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N. Engl. J. Med., 339, 21–26.CrossRefGoogle ScholarPubMed
Morgan, G. J., Davies, F. E., Gregory, W. M., et al. (2010). First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet, 376, 1989–1999.CrossRefGoogle ScholarPubMed
Morgan, G. J., Davies, F. E., Gregory, W. M., et al. (2011). Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood, 118, 1231–1238.CrossRefGoogle ScholarPubMed
Morris, P., Correa, D., Yahalom, J., et al., (2013). Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J. Clin. Oncol., 31, 3971–3979.CrossRef
Morris, S. L. (2012). Skin lymphoma. Clin. Oncol. (R. Coll. Radiol.), 24, 371–385.CrossRefGoogle ScholarPubMed
Morris, S. L., McGovern, M., Bayne, S., et al. (2013). Results of a 5-week schedule of modern total skin electron beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 86, 936–941.CrossRefGoogle ScholarPubMed
Moskowitz, C. H., Matasar, M. J., Zelenetz, A. D., et al. (2012). Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood, 119, 1665–1670.CrossRefGoogle ScholarPubMed
NICE. (2011). Referral Guidelines for Suspected Cancer. NICE Clinical Guideline 27. Issued June 2005, last modified April 2011.London: National Institute for Health and Care Excellence.
Nogová, L., Rudiger, T. and Engert, A. (2006). Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematology, 2006, 266–272.CrossRefGoogle Scholar
Pfreundschuh, M., Kuhnt, E., Trümper, L., et al. (2011). CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol., 12, 1013–1022.CrossRefGoogle ScholarPubMed
Philip, T., Guglielmi, C., Hagenbeed, A., et al. (1995). Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 333, 1540–1545.CrossRefGoogle ScholarPubMed
Pugh, T. J., Ballonoff, A., Newman, F., et al. (2010). Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation. Cancer, 116, 3843–3851.CrossRefGoogle ScholarPubMed
Radford, J., Illidge, T., Counsell, N., et al. (2015). Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N. Engl. J. Med., 372, 1598–1607.CrossRef
Roman, E. and Smith, A. G. (2011). Epidemiology of lymphomas. Histopathology, 58, 4–14.CrossRefGoogle ScholarPubMed
Rummel, M. J., Niederle, N., Maschmeyer, G., et al. (2013). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet, 381, 1203–1210.CrossRefGoogle ScholarPubMed
Safar, V., Dupuis, J., Itti, E., et al. (2012). Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-Cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J. Clin. Oncol., 30, 184–190.CrossRefGoogle ScholarPubMed
Salles, G., Seymour, J. F., Offner, F., et al. (2011). Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, 377, 42–51.CrossRefGoogle ScholarPubMed
Sasaki, R., Yasuda, K., Abe, E., et al. (2012). Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 82, 626–634.CrossRefGoogle ScholarPubMed
Scarisbrick, J. J., Morris, S., Azurdia, R., et al. (2013). U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br. J. Dermatol., 168, 192–200.CrossRefGoogle ScholarPubMed
Shipp, M. A. (1993). A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med., 329, 987–994.Google Scholar
Solal-Céligny, P., Roy, P., Colombat, P., et al. (2004). Follicular Lymphoma International Prognostic Index. Blood, 104, 1258–1265.CrossRefGoogle ScholarPubMed
Somers, R., Burgers, J. M., Qasim, M., et al. (1987). EORTC trial non-Hodgkin lymphomas. Eur. J. Cancer Clin. Oncol., 23, 283–293.CrossRefGoogle ScholarPubMed
Soutar, R., Lucraft, H., Jackson, G., et al. (2004). Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Clin. Oncol. (R. Coll. Radiol.), 16, 405–413.CrossRefGoogle ScholarPubMed
Specht, L., Dabaja, B., Illidge, T., et al. (2015). Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int. J. Radiat. Oncol. Biol. Phys., 92, 32–39.CrossRef
Specht, L., Yahalom, J., Illidge, T., et al. (2014). Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG).Int. J. Radiat. Oncol. Biol. Phys., 89, 954–962.CrossRefGoogle ScholarPubMed
Stiff, P. J., Unger, J. M., Cook, J. R., et al. (2013). Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med., 369, 1681–1690.CrossRefGoogle ScholarPubMed
Swerdlow, A. J., Cooke, R., Bates, A., et al. (2012). Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. J. Clin. Oncol., 30, 2745–2752.CrossRefGoogle ScholarPubMed
Swerdlow, S. H., Campo, E., Harris, N. L., et al. (2008). WHO Classification of Tumour of Haematopoietic and Lymphoid Tissues.Lyon: IARC Press.Google Scholar
Thomas, J., Ferme, C., Noordijk, E., et al. (2004). Six cycles of EBVP followed by 36 Gy involved-field irradiation vs. no irradiation in favourable supradiaphragmatic clinical stages I–II Hodgkin's lymphoma: the EORTC-GELA strategy in 771 patients.Eur. J. Haematol., 73(Suppl. 64), Abstr. 40.Google Scholar
Tournier-Rangeard, L., Lapeyre, M., Graff-Caillaud, P., et al. (2006). Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: a dose greater than 45 Gy to the target volume improves the local control. Int. J. Radiat. Oncol. Biol. Phys., 64, 1013–1017.CrossRefGoogle ScholarPubMed
Tsang, R. W., Gospodarowicz, M. K., Pintilie, M., et al. (2001). Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int. J. Radiat. Oncol. Biol. Phys., 50, 113–120.CrossRefGoogle Scholar
Tse, E. and Kwong, Y. L. (2013). How I treat NK/T-cell lymphomas. Blood, 121, 4997–5005.CrossRefGoogle Scholar
Vitolo, U., Chiappella, A., Ferreri, A. J. M., et al. (2011). First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J. Clin. Oncol., 29, 2766–2772.CrossRefGoogle ScholarPubMed
von Tresckow, B., Plütschow, A., Fuchs, M., et al. (2012). Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 Trial. J. Clin. Oncol., 30, 907–913.CrossRefGoogle Scholar
Willemze, R., Hodak, E., Zinzani, P. L., et al. (2013). Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 24(Suppl. 6), vi149–vi154.CrossRefGoogle ScholarPubMed
Yahalom, J., Illidge, T., Specht, L., et al. (2015). Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int. J. Radiat. Oncol. Biol. Phys., 92, 11–31.CrossRef
Yahalom, J. and Mauch, P. (2002). The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann. Oncol., 13, 79–83.CrossRefGoogle ScholarPubMed
Younes, A., Gopal, A. K., Smith, S. E., et al. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol., 30, 183–189.Google ScholarPubMed
Ziepert, M., Hasenclever, D. and Kuhnt, E. (2010). Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-Cell lymphoma in the rituximab era. J. Clin. Oncol., 28, 2373–2380.CrossRefGoogle ScholarPubMed
Zucca, E., Conconi, A., Laszlo, D., et al. (2013). Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J. Clin. Oncol., 31, 565–572.CrossRefGoogle ScholarPubMed

Send book to Kindle

To send this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats
×

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats
×